Antibodies developed at the University of California, Riverside (UCR), and licensed to Releviate Therapeutics may contribute to a significant advancement in the treatment of chronic pain as an alternative to opioids. Every year, more than 50 million adults in the United States suffer from chronic pain, a serious condition that negatively affects quality of life...
The Office of Technology Partnerships (OTP) facilitates the development and commercialization of ideas emanating from The University of California Riverside (UCR) and the community for the benefit of society. The licensing of proteasome and immunoproteasome inhibitors to Lodo Therapeutics is an example of UCR OTP’s success as a bridge between academia and industry. On September...